Bye, Bye Byetta: Teva To Take AstraZeneca's GLP-1 Agonist Generic Two Years Early
This article was originally published in The Pink Sheet Daily
Executive Summary
First in class is the first to fall, and Byetta could go even earlier than the October 2017 date set in Teva settlement since AstraZeneca still faces a generic challenge from Amneal – and a direct attack on its patents from Sanofi.